HC Wainwright Begins Coverage on Immunic (NASDAQ:IMUX)

HC Wainwright started coverage on shares of Immunic (NASDAQ:IMUX) in a report released on Monday, Marketbeat.com reports. The firm issued a buy rating and a $10.00 price target on the stock. HC Wainwright also issued estimates for Immunic’s Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.95) EPS, FY2025 earnings at ($0.85) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.23) EPS.

Other equities research analysts have also issued research reports about the company. Leerink Partnrs raised Immunic to a “strong-buy” rating in a research note on Monday, September 9th. EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. Leerink Partners restated an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a report on Monday, September 9th. StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Finally, B. Riley initiated coverage on shares of Immunic in a research report on Tuesday, August 27th. They set a “buy” rating and a $6.00 price target for the company. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $11.80.

Immunic Price Performance

IMUX stock opened at $1.20 on Monday. The firm has a 50 day simple moving average of $1.37 and a two-hundred day simple moving average of $1.34. The stock has a market cap of $108.09 million, a PE ratio of -0.98 and a beta of 1.88. Immunic has a one year low of $0.97 and a one year high of $2.11.

Insiders Place Their Bets

In related news, Director Richard Alan Rudick acquired 87,300 shares of Immunic stock in a transaction on Tuesday, November 12th. The shares were acquired at an average cost of $1.15 per share, with a total value of $100,395.00. Following the transaction, the director now owns 87,300 shares in the company, valued at $100,395. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Immunic

Institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC bought a new position in Immunic in the first quarter worth about $9,266,000. Vanguard Group Inc. grew its holdings in shares of Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares during the period. Ikarian Capital LLC raised its position in shares of Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after acquiring an additional 1,162,378 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the period. Finally, Jane Street Group LLC lifted its stake in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the period. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.